Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in Rare Neuroendocrine Tumors
NCT00958841Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2009
- Primary completion
- Jun 2015
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of pasireotide LAR in Pancreatic neuroendocrine tumor (PanNET), pituitary neuroendocrine tumor (PitNET), Nelson's syndrome, ectopic adrenocorticotropic hormone syndrome (EAS), sponsored by Novartis. Started Sep 2009; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)pituitary neuroendocrine tumor (PitNET)Nelson's syndromeectopic adrenocorticotropic hormone syndrome (EAS)
Beyond the preview
Go deeper on NCT00958841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958841.